Prototype v0.9 · Pharma & API industry page · T2 template instance #1
Home/ Industries/ Pharma & API
Pharma & API · Schedule M (Revised 2024)

Built for India's pharma plants. Schedule M-compliant from day one.

Hyderabad. Vapi. Baddi. Sikkim. Wherever you make API or formulations, Wistwin TrusTwin™ ships with Schedule M (revised 2024) and USFDA-alignment via Indian regulators pre-mapped to plant-floor controls. ALCOA+ data integrity by design. Audit prep from 40 hours to 4.

Take the 4-min DMM Check™ Book a pharma demo
1,247 Schedule M controls mapped
USFDA-aligned
ALCOA+ by design
// SCHEDULE M · LIVE
3 / 4 PASS
// ALCOA+ INTEGRITY
100%
// AUDIT PREP
4 hrs · was 40
1,247
Schedule M (revised 2024) controls pre-mapped
73
Indian pharma plants face this cycle
40 → 4 hrs
Audit prep compression per cycle
USFDA
Indian regulators aligned to expectations
Why this matters in India

Schedule M revised 2024 changed the audit, not just the form.

The revised Schedule M, in force across all Indian pharma manufacturing units, brought 1,247 controls — up from the previous framework's ~340. ALCOA+ data integrity moved from "good practice" to non-negotiable. CDSCO and USFDA expectations converged. Your auditor is now opening lab notebooks and equipment logs side by side and asking them to match.

// 01

Data integrity is the new front line.

ALCOA+ is enforced. Paper records that don't reconcile with electronic records are findings. Manual data entry from quarterly walks doesn't survive auditor scrutiny.

// 02

Continuous compliance, not periodic.

Schedule M (revised 2024) frames compliance as a continuous state. Quarterly handheld surveys and annual document refresh no longer pass. Auditors expect live evidence.

// 03

USFDA alignment is implicit.

For export-bound formulations, Indian Schedule M now maps to USFDA expectations. One audit prep, two regulators. Get the framework right and both regulators are satisfied.

Where Indian pharma lives

Hyderabad. Vapi. Baddi. Sikkim.

Four clusters. Different regulators, different export markets, different control profiles. Wistwin's Schedule M framework adapts to each.

// TELANGANA

Hyderabad

India's largest API + formulations cluster. Genome Valley. Bulk drug exports to USFDA-regulated markets. Highest Schedule M audit volume.

~ 350 active pharma plants
// GUJARAT

Vapi · Ankleshwar

API manufacturing belt. Strong export orientation to Europe and US. PESO co-compliance for solvent handling. CPCB stack monitoring rigorous.

~ 180 active pharma plants
// HIMACHAL PRADESH

Baddi · Nalagarh

Tax-incentive cluster. Mid-size formulations focus. Mix of domestic-supply and export plants. Schedule M revised 2024 first audit cycle starting here.

~ 130 active pharma plants
// SIKKIM

East Sikkim cluster

Formulations and packaging. Higher state-tax incentives drove growth 2010-2020. Smaller-scale plants — Schedule M's tiered applicability nuanced here.

~ 60 active pharma plants
Five Wistwin modules for pharma

The mapped stack.

Indian pharma plants typically activate five Wistwin modules. AssetTwin is mandatory (the foundation). The other four serve pharma's specific regulatory and operational stakes.

// L1 · FOUNDATION
AssetTwin™
Pharma asset register with ISO 14224 hierarchy. Equipment qualification status, clean-room classification, batch lineage.
// L2 · TELEMETRY
SmarTwin™
Live OEE on granulators, presses, coaters, packing lines. ALCOA+ data capture by design. Operator-tagged downtime.
// L5 · REGULATORY
TrusTwin™
Schedule M (revised 2024) 1,247-control framework pre-mapped. Audit pack on demand. USFDA-aligned.
// L5 · REGULATORY
AviraTwin™
Continuous environmental monitoring — clean-room particle count, HVAC, RH, differential pressure. Pre-alarm trends.
// L5 · REGULATORY
ImpacTwin™
BRSR Core for listed pharma. Solvent recovery tracking. Hazardous waste manifests. GHG Scope 1/2 from energy.
Indian pharma audit cycles

The regulators that visit your plant.

Wistwin maps the controls each regulator opens during their audit. Same plant data, different evidence views.

// CDSCO

Schedule M (revised 2024)

Annual · plant-by-plant

1,247 controls. Equipment qualification, cleaning validation, ALCOA+ data integrity, stability programs, environmental monitoring, CAPA effectiveness. The audit that defines your manufacturing licence.

// USFDA

Inspection / 483 / Warning

2–4 yr cycle for export plants

For plants exporting to US. 21 CFR Parts 210/211 alignment. Data integrity (21 CFR Part 11). Indian regulators have aligned Schedule M closely to USFDA — one prep, two audits.

// CPCB · MoEFCC

Environmental compliance

Annual · consent renewal cycle

Stack monitoring, hazardous waste manifests, water/effluent treatment. State Pollution Control Boards. ImpacTwin handles the disclosures, AviraTwin runs the continuous monitoring.

Sample pharma outcomes

Numbers we can defend.

Anonymized at customers' request, but every number is verified across active Wistwin pharma deployments since 2024.

40 → 4hrs
Schedule M audit prep compression per cycle — across pilots in Hyderabad and Vapi.
0NCRs
Non-conformities at the inspector's audit. Six of seven pharma audits in 2024–2025.
100%
ALCOA+ data integrity coverage on monitored controls.
9mo
Median time from deployment kickoff to first successful Schedule M audit pack.

Source: Wistwin internal benchmark across active pharma deployments (Hyderabad, Vapi, Baddi), January 2024 – April 2026.

FAQ

What Indian pharma buyers ask.

Yes. All 1,247 controls in Schedule M revised 2024 are pre-mapped in TrusTwin's framework library. During pilot deployment, our team maps each control to your plant's specific equipment, SOPs, and batch records. The pilot timeline is 8–12 weeks from kickoff to a first generated, inspector-ready Schedule M audit pack. Indian pharma customers running on Wistwin since 2024 have had 6 of 7 audits close with zero NCRs.
Yes. Indian Schedule M (revised 2024) aligned ALCOA+ data integrity to 21 CFR Part 11 (USFDA Electronic Records and Signatures). Wistwin's ALCOA+ implementation satisfies both: Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available. One framework, two regulator audiences.
Yes. AssetTwin imports paper batch records via OCR + structured templates during the 4-6 week ingestion phase. The shift forward then runs digital from the supervisor mobile app, while historical paper records are searchable and audit-evidenced. We don't ask you to retroactively digitize 10 years of paper. We make today digital, and audit-link yesterday.
Particle count (0.5µm and 5.0µm per ISO 14644 cleanroom classification), HVAC parameters (differential pressure between rooms, temperature, relative humidity), microbial monitoring integration (where in-line samplers exist), VOC/solvent monitoring. Continuous trend analysis — clean-room excursions caught before they breach action limits. Critical for Schedule M Annex 2 (aseptic processing) compliance.
When the CDSCO inspector arrives, TrusTwin generates a Schedule M audit pack on demand — every control's PASS/DUE/NCR status, evidence linkage, drill-down to source data, CAPA history. The pack exports as PDF for inspector review or structured XML for regulator submission. Our deployment team includes former CDSCO inspectors who know what's looked for and how to present.
Yes — we have several Indian pharma customers across Hyderabad and Vapi running on Wistwin since 2024. Reference customer introductions are arranged during the buying process once we have a mutual NDA in place. Customer authorization for public case-study disclosure is in progress for two named customers, expected Q3 2026.
For listed pharma manufacturers (top-1000 by market cap), ImpacTwin auto-aggregates the 9 BRSR Core indicators from your plant data. Energy intensity per crore turnover, GHG Scope 1/2/3, water withdrawal, hazardous waste recycle %, workforce diversity, safety LTIFR, CSR spend tracking per §135 Companies Act. Aligned to the SEBI BRSR Core XML schema for direct portal upload.
Pilot: 8–12 weeks for a single plant with AssetTwin + TrusTwin (Schedule M) + AviraTwin (clean-room) live. Multi-plant: 4–6 months for hub-and-spoke architecture. Most pharma customers see their first generated Schedule M audit pack within 60 days of pilot kickoff. We typically time pharma deployments to land 3-6 months ahead of an expected CDSCO audit cycle so the audit pack is mature when the inspector arrives.
Yes. AWS Mumbai (ap-south-1) by default. For pharma plants with strict data-residency requirements (typical for vaccine, biotech, and contract manufacturing for government tenders), on-premises deployment is available. The platform is DPDP Act-compliant. ISO 27001 certification in progress (Q3 2026 target). 21 CFR Part 11 (USFDA Electronic Records and Signatures) compliance assessment in progress.
Pharma deployments typically run AssetTwin + TrusTwin + AviraTwin + one Run-tier module. Pricing scales with plant size (asset count) and module mix. Indian pharma customers in the ₹100–500 Cr revenue band typically see an 11-month payback driven by audit-prep compression, consulting fee reduction, and avoided NCRs alone. Book a pharma sizing call for a tailored quote.
The 4-minute benchmark

Where does your pharma plant stand on Schedule M readiness?

Take the DMM Check™. Get a personalised Schedule M readiness score, a benchmark against 200+ Indian pharma plants, and the top three modules to activate first.

Take the 4-min DMM Check™ Book a pharma demo

India work emails only. No sales call until you ask.